Abstract | PURPOSE OF REVIEW: RECENT FINDINGS:
Rifaximin is a gastrointestinal-selective antibiotic with a broad spectrum of antimicrobial activity, an excellent safety profile, minimal drug interactions, and negligible impact on the intestinal microbiome. Rifaximin is currently approved in the United States for the treatment of travelers' diarrhea caused by noninvasive diarrheagenic Escherichia coli and is approved in more than 30 other countries for a variety of gastrointestinal disorders. Considerable research with this medication has been conducted for the treatment and prevention of travelers' diarrhea, the treatment of portal systemic encephalopathy, Clostridium difficile infection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, pouchitis, and colonic diverticular disease. SUMMARY:
|
Authors | Hoonmo L Koo, Herbert L DuPont |
Journal | Current opinion in gastroenterology
(Curr Opin Gastroenterol)
Vol. 26
Issue 1
Pg. 17-25
(Jan 2010)
ISSN: 1531-7056 [Electronic] United States |
PMID | 19881343
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
- Anti-Infective Agents
- Rifamycins
- Rifaximin
|
Topics |
- Anti-Infective Agents
(administration & dosage, pharmacology)
- Bacterial Infections
(diagnosis, drug therapy)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Dysentery
(drug therapy, microbiology, prevention & control)
- Female
- Follow-Up Studies
- Gastroenteritis
(drug therapy, microbiology)
- Humans
- Male
- Randomized Controlled Trials as Topic
- Rifamycins
(pharmacology, therapeutic use)
- Rifaximin
- Risk Assessment
- Travel
- Treatment Outcome
|